SB298 Summary

• Establishes the Abortion-Inducing Drug Safety Act to regulate abortion-inducing drugs, specifically mifepristone, requiring adherence to FDA-approved protocols with specific dosages and administration procedures through 49 days of gestation.

• Requires physicians to conduct in-person examinations documenting gestational age and intrauterine location before prescribing abortion-inducing drugs, provide patients with drug labels, maintain signed contracts with backup physicians for complications, and schedule follow-up visits at approximately 14 days.

• Mandates physicians report adverse events to the FDA via Medwatch Reporting System and the Department of Public Health within three days of occurrence.

• Establishes criminal penalties of Class C felony for intentional, knowing, or reckless violations, with exemption for pregnant women receiving the drug; exempts pregnant women from civil liability.

• Provides civil remedies including malpractice actions for actual and punitive damages, professional disciplinary action through the State Board of Medical Examiners, and wrongful death claims; awards reasonable attorney's fees to prevailing plaintiffs.